Cargando…
A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations
BACKGROUND: PIK3CA-related disorders include vascular malformations and overgrowth of various tissues that are caused by postzygotic, somatic variants in the gene encoding phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha. These mutations result in activation of the PI3K/AKT/mTOR signalin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268514/ https://www.ncbi.nlm.nih.gov/pubmed/34238334 http://dx.doi.org/10.1186/s13023-021-01929-8 |
_version_ | 1783720375180328960 |
---|---|
author | Canaud, Guillaume Hammill, Adrienne M. Adams, Denise Vikkula, Miikka Keppler-Noreuil, Kim M. |
author_facet | Canaud, Guillaume Hammill, Adrienne M. Adams, Denise Vikkula, Miikka Keppler-Noreuil, Kim M. |
author_sort | Canaud, Guillaume |
collection | PubMed |
description | BACKGROUND: PIK3CA-related disorders include vascular malformations and overgrowth of various tissues that are caused by postzygotic, somatic variants in the gene encoding phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha. These mutations result in activation of the PI3K/AKT/mTOR signaling pathway. The goals of this review are to provide education on the underlying mechanism of disease for this group of rare conditions and to summarize recent advancements in the understanding of, as well as current and emerging treatment options for PIK3CA-related disorders. MAIN BODY: PIK3CA-related disorders include PIK3CA-related overgrowth spectrum (PROS), PIK3CA-related vascular malformations, and PIK3CA-related nonvascular lesions. Somatic activating mutations (predominantly in hotspots in the helical and kinase domains of PIK3CA, but also in other domains), lead to hyperactivation of the PI3K signaling pathway, which results in abnormal tissue growth. Diagnosis is complicated by the variability and overlap in phenotypes associated with PIK3CA-related disorders and should be performed by clinicians with the required expertise along with coordinated care from a multidisciplinary team. Although tissue mosaicism presents challenges for confirmation of PIK3CA mutations, next-generation sequencing and tissue selection have improved detection. Clinical improvement, radiological response, and patient-reported outcomes are typically used to assess treatment response in clinical studies of patients with PIK3CA-related disorders, but objective assessment of treatment response is difficult using imaging (due to the heterogeneous nature of these disorders, superimposed upon patient growth and development). Despite their limitations, patient-reported outcome tools may be best suited to gauge patient improvement. New therapeutic options are needed to provide an alternative or supplement to standard approaches such as surgery and sclerotherapy. Currently, there are no systemic agents that have regulatory approval for these disorders, but the mTOR inhibitor sirolimus has been used for several years in clinical trials and off label to address symptoms. There are also other agents under investigation for PIK3CA-related disorders that act as inhibitors to target different components of the PI3K signaling pathway including AKT (miransertib) and PI3K alpha (alpelisib). CONCLUSION: Management of patients with PIK3CA-related disorders requires a multidisciplinary approach. Further results from ongoing clinical studies of agents targeting the PI3K pathway are highly anticipated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01929-8. |
format | Online Article Text |
id | pubmed-8268514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82685142021-07-09 A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations Canaud, Guillaume Hammill, Adrienne M. Adams, Denise Vikkula, Miikka Keppler-Noreuil, Kim M. Orphanet J Rare Dis Review BACKGROUND: PIK3CA-related disorders include vascular malformations and overgrowth of various tissues that are caused by postzygotic, somatic variants in the gene encoding phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha. These mutations result in activation of the PI3K/AKT/mTOR signaling pathway. The goals of this review are to provide education on the underlying mechanism of disease for this group of rare conditions and to summarize recent advancements in the understanding of, as well as current and emerging treatment options for PIK3CA-related disorders. MAIN BODY: PIK3CA-related disorders include PIK3CA-related overgrowth spectrum (PROS), PIK3CA-related vascular malformations, and PIK3CA-related nonvascular lesions. Somatic activating mutations (predominantly in hotspots in the helical and kinase domains of PIK3CA, but also in other domains), lead to hyperactivation of the PI3K signaling pathway, which results in abnormal tissue growth. Diagnosis is complicated by the variability and overlap in phenotypes associated with PIK3CA-related disorders and should be performed by clinicians with the required expertise along with coordinated care from a multidisciplinary team. Although tissue mosaicism presents challenges for confirmation of PIK3CA mutations, next-generation sequencing and tissue selection have improved detection. Clinical improvement, radiological response, and patient-reported outcomes are typically used to assess treatment response in clinical studies of patients with PIK3CA-related disorders, but objective assessment of treatment response is difficult using imaging (due to the heterogeneous nature of these disorders, superimposed upon patient growth and development). Despite their limitations, patient-reported outcome tools may be best suited to gauge patient improvement. New therapeutic options are needed to provide an alternative or supplement to standard approaches such as surgery and sclerotherapy. Currently, there are no systemic agents that have regulatory approval for these disorders, but the mTOR inhibitor sirolimus has been used for several years in clinical trials and off label to address symptoms. There are also other agents under investigation for PIK3CA-related disorders that act as inhibitors to target different components of the PI3K signaling pathway including AKT (miransertib) and PI3K alpha (alpelisib). CONCLUSION: Management of patients with PIK3CA-related disorders requires a multidisciplinary approach. Further results from ongoing clinical studies of agents targeting the PI3K pathway are highly anticipated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01929-8. BioMed Central 2021-07-08 /pmc/articles/PMC8268514/ /pubmed/34238334 http://dx.doi.org/10.1186/s13023-021-01929-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Canaud, Guillaume Hammill, Adrienne M. Adams, Denise Vikkula, Miikka Keppler-Noreuil, Kim M. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title | A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title_full | A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title_fullStr | A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title_full_unstemmed | A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title_short | A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations |
title_sort | review of mechanisms of disease across pik3ca-related disorders with vascular manifestations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268514/ https://www.ncbi.nlm.nih.gov/pubmed/34238334 http://dx.doi.org/10.1186/s13023-021-01929-8 |
work_keys_str_mv | AT canaudguillaume areviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT hammilladriennem areviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT adamsdenise areviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT vikkulamiikka areviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT kepplernoreuilkimm areviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT canaudguillaume reviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT hammilladriennem reviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT adamsdenise reviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT vikkulamiikka reviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations AT kepplernoreuilkimm reviewofmechanismsofdiseaseacrosspik3carelateddisorderswithvascularmanifestations |